Centrone Natalia, Serrano Uson Junior Pedro Luiz
Center for Personalized Medicine, Hospital Israelita Albert Einstein, Sao Paulo 05651-901, Brazil.
World J Gastrointest Oncol. 2024 Dec 15;16(12):4753-4756. doi: 10.4251/wjgo.v16.i12.4753.
Hepatocellular carcinoma (HCC) is a lethal disease and unfortunately, most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization (TACE) was the mainstream treatment. Lately, the incorporation of immune checkpoint inhibitors and antiangiogenics for the treatment of metastatic disease has paved the way for significant improvements in the treatment of initially uHCC. In this editorial we will discuss an article that evaluated ICI combinations with lenvatinib and TACE for the treatment of uHCC patients, and highlight future advances in the field.
肝细胞癌（HCC）是一种致命疾病，不幸的是，大多数患者被诊断为不可切除/晚期阶段，总体预后较差。对于最初不可切除的HCC（uHCC）患者，经动脉化疗栓塞术（TACE）是主流治疗方法。最近，免疫检查点抑制剂和抗血管生成药物用于转移性疾病的治疗，为最初uHCC的治疗带来显著改善铺平了道路。在这篇社论中，我们将讨论一篇评估ICI与乐伐替尼联合TACE治疗uHCC患者的文章，并强调该领域未来的进展。
